Bristol Myers Squibb — Pharmaceutical Intelligence | Humanexa Signals

ClinicalJune 17, 2026

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

A novel lactylation-related prognostic model (CM-LP11) effectively stratifies cutaneous melanoma patients into high- and low-risk groups based on overall survival.

Recent signals(27)

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

FDA Accepts Supplemental Application for POMALYST by Bristol

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)

FDA Accepts Supplemental Application for OPDIVO QVANTIG by Bristol-Myers Squibb

FDA Accepts Supplement Application for OPDIVO (Nivolumab) by Bristol Myers Squibb

Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation

Bristol-Myers Squibb Evaluates Pomalidomide Outcomes in Relapsed/Refractory Multiple Myeloma

FDA Submission Status Update for ABANTA (Apixaban) by AZURITY

FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb

BMS initiates trial for Imzokitug in NSCLC with Pumitamig and chemotherapy

Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy

FDA Accepts Supplemental Application for Eliquis (Apixaban)

Bristol-Myers Squibb Evaluates KarXT for Bipolar-I Disorder Manic Episodes

Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial

BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab

BioNTech's Pumitamig Phase III Trial in Triple-Negative Breast Cancer Underway

FDA Accepts Supplemental Application for YERVOY (ipilimumab)

FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb

FDA Accepts Supplement Application for YERVOY (ipilimumab)

FDA Accepts Supplement Application for YERVOY (ipilimumab) by Bristol Myers Squibb

Study on Treatment Patterns for Nivolumab in Community Oncology Settings

Phase II Trial of Nivolumab for Persistent Cervical Cancer Shows Potential Efficacy

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

Upcoming catalysts

Regulatory activity(13)

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

FDA Accepts Supplemental Application for POMALYST by Bristol

FDA Accepts Supplemental Application for REVLIMID by Bristol Myers Squibb

FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)

FDA Accepts Supplemental Application for OPDIVO QVANTIG by Bristol-Myers Squibb

FDA Accepts Supplement Application for OPDIVO (Nivolumab) by Bristol Myers Squibb

FDA Submission Status Update for ABANTA (Apixaban) by AZURITY

FDA Acceptance of Supplemental NDA for REVLIMID by Bristol Myers Squibb

FDA Accepts Supplemental Application for Eliquis (Apixaban)

FDA Accepts Supplemental Application for YERVOY (ipilimumab)

FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb

FDA Accepts Supplement Application for YERVOY (ipilimumab)

FDA Accepts Supplement Application for YERVOY (ipilimumab) by Bristol Myers Squibb

Clinical activity(13)

Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation

Bristol-Myers Squibb Evaluates Pomalidomide Outcomes in Relapsed/Refractory Multiple Myeloma

BMS initiates trial for Imzokitug in NSCLC with Pumitamig and chemotherapy

Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy

Bristol-Myers Squibb Evaluates KarXT for Bipolar-I Disorder Manic Episodes

BMS's Navlimetostat in NSCLC Trial vs. Placebo and Pembrolizumab

BioNTech's Pumitamig Phase III Trial in Triple-Negative Breast Cancer Underway

Study on Treatment Patterns for Nivolumab in Community Oncology Settings

Phase II Trial of Nivolumab for Persistent Cervical Cancer Shows Potential Efficacy

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

Competitive activity(1)

Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial

Assets

Therapeutic areas

Indications

Get signals before the market moves